Company intelligence / Profile preview

Procypra Therapeutics

Ownership: Private
Development stage: Phase 1

Overview

Procypra Therapeutics is developing Cu(II)ATSM, a small molecule therapy for neurodegenerative diseases such as ALS and Parkinson’s disease. The company has completed preclinical studies demonstrating efficacy in animal models and has initiated Phase 1 clinical trials targeting ALS/Parkinson’s disease.[1][2]

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Cu(II)ATSM

Phase 1

Indications: Amyotrophic lateral sclerosis, Parkinson's disease

Partnerships

The University of Melbourne[7]

Beyond the preview

Go deeper on Procypra Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Procypra Therapeutics.

Explore the full profile